抗血小板结合抗凝治疗并发上消化道出血的临床有效性研究  

Study on the Clinical Effectiveness of Antiplatelet Combined with Anticoagulation in the Treatment of Upper Gastrointestinal Bleeding

作　　者：周涛[1] ZHOU Tao(Department of Internal Medicine,Linyi Mental Health Center,Linyi,Shandong Province,276000 China)

机构地区：[1]临沂市精神卫生中心内科,山东临沂276000

出　　处：《中外医疗》2022年第6期22-25,共4页China & Foreign Medical Treatment

摘　　要：目的评价并发上消化道出血患者应用抗血小板结合抗凝治疗的临床有效性。方法简单随机选择该院2020年2月—2021年2月就诊的100例并发上消化道出血患者为研究对象,按照随机数表法分为两组,对照组与观察组名50例。为对照组提供常规治疗,为观察组提供抗血小板结合抗凝治疗,比较两组并发上消化道出血患者的临床治疗效果。结果观察组治疗总有效率(98.00%)高于对照组(78.00%),差异有统计学意义(χ^(2)=9.470,P<0.05)。观察组血细胞比容(36.23±3.28)%高于对照组(30.12±4.31)%,观察组门静脉血流量(544.23±89.52)mL/min和脾静脉血流量(277.23±80.52)mL/min小于对照组(625.63±90.52)、(338.51±81.42)mL/min,差异有统计学意义(P<0.05)。观察组的输血量(242.65±49.52)mL小于对照组(433.56±61.52)mL,观察组的止血时间(23.46±4.52)h与住院时间(8.16±2.88)d短于对照组(35.69±6.64)h、(12.05±2.49)d,差异有统计学意义(P<0.05)。观察组不良症状(黑便、呕血、大便潜血阳性、胃液潜血阳性)发生率(6.00%)低于对照组(30.00%),差异有统计学意义(P<0.05)。观察组红细胞计数(2.88±0.14)×10^(12)/L、血红蛋白(82.46±5.96)g/L高于对照组(2.70±0.15)×10^(12)/L、(80.15±5.15)g/L,差异有统计学意义(P<0.05)。结论并发上消化道出血患者临床治疗中应用抗血小板与抗凝治疗相结合,可以提升临床有效率,值得在临床中予以推广和使用。Objective To evaluate the clinical effectiveness of antiplatelet combined anticoagulation therapy in patients with upper gastrointestinal bleeding.Methods 100 patients with upper gastrointestinal hemorrhage who were treated in this hospital from February 2020 to February 2021 were random selected as the research objects.Divided into two groups according to the random number table method,with 50 cases in the control group and the observation group.Provided conventional treatment for the control group and antiplatelet combined anticoagulation treatment for the observation group.Compared the clinical treatment effects of the two groups of patients with upper gastrointestinal bleeding.Results The total effective rate of treatment in the observation group(98.00%)was higher than that in the control group(78.00%),and the difference was statistically significant(χ^(2)=9.470,P<0.05).The hematocrit(36.23±3.28)%of the observation group was higher than that of the control group(30.12±4.31)%.The blood flow of the portal vein(544.23±89.52)mL/min and the blood flow of the splenic vein(277.23±80.52)mL/min of the observation group were lower than those of the control group(625.63±90.52),(338.51±81.42)mL/min,the difference was statistically significant(P<0.05).The blood transfusion volume of the observation group(242.65±49.52)mL was less than that of the control group(433.56±61.52)mL,and the hemostasis time(23.46±4.52)h and hospitalization time(8.16±2.88)d of the observation group was shorter than that of the control group(35.69±6.64)h,(12.05±2.49)d,the difference was statistically significant(P<0.05).The incidence of adverse symptoms(black stool,hematemesis,positive stool occult blood,positive gastric occult blood)in the observation group(6.00%)was lower than that in the control group(30.00%),and the difference was statistically significant(P<0.05).The red blood cell count(2.88±0.14)×10^(12)/L and hemoglobin(82.46±5.96)g/L in the observation group were higher than those in the control group(2.70±0.15)×10^(12)/L

关 键 词：抗血小板治疗 抗凝治疗 上消化道出血 血细胞比容 门静脉血流量 输血量 

分 类 号：R573[医药卫生—消化系统]